Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methanobrevibacter smithii is a single-celled, anaerobic archaeon that is the predominant methanogenic microorganism in the human gut microbiota. It plays a crucial role in the efficient digestion of complex polysaccharides by consuming hydrogen and carbon dioxide to produce methane, thereby enhancing energy extraction from food. High concentrations have been associated with increased risk of obesity and constipation-predominant IBS, making it a potential therapeutic target for metabolic disorders.
Reduction of Methanobrevibacter smithii abundance via targeted antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methanobrevibacter smithii.